- NCIt
- C8964
Loading cancer entity…
Loading cancer entity…
Clinical trials
25 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07832747 | A Study of DCC-3014 to Evaluate the Efficacy, Safety, and Pharmacokinetics in Subjects With TGCT | not yet recruiting | Phase 2 | 18 | Ono Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07499362 | Study of Pimicotinib in Japanese Participants With Tenosynovial Giant Cell Tumor (TGCT) (J-MANEUVER) | recruiting | Phase 2 | 20 | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyINDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07075471 | MOVE: Tenosynovial Giant Cell Tumor (TGCT) Real-World Participant Experience With Vimseltinib(MOVE) | recruiting | — | 100 | Deciphera Pharmaceuticals, LLCINDUSTRY | 1 | Jul 27, 2026 | clinicaltrials |
Data updated 5 days agoSource updated Sep 22, 2026source: clinicaltrials
| NCT07707882 | Neoadjuvant Pimicotinib Combined With Surgery Versus Upfront Surgery for Diffuse Tenosynovial Giant Cell Tumor(NEXPERT) | not yet recruiting | Phase 2 | 84 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT04488822 | A Study of the Efficacy and Safety of Pexidartinib in Adult Subjects With TGCT(PLX3397) | active not recruiting | Phase 3 | 40 | Daiichi Sankyo Co., Ltd.INDUSTRY | 2 | Jun 26, 2026 | clinicaltrials |
| NCT03069469 | Study of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor | active not recruiting | Phase 1 / Phase 2 | 120 | Deciphera Pharmaceuticals, LLCINDUSTRY | 9 | Jun 25, 2026 | clinicaltrials |
| NCT04703322 | A Study of Pexidartinib in Tenosynovial Giant Cell Tumor in Japan | completed | Phase 2 | 9 | Daiichi Sankyo Co., Ltd.INDUSTRY | 1 | Jun 24, 2026 | clinicaltrials |
| NCT05804045 | Study of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor (MANEUVER) | active not recruiting | Phase 3 | 94 | Abbisko Therapeutics Co, LtdINDUSTRY | 7 | May 4, 2026 | clinicaltrials |
| NCT05059262 | Study of Vimseltinib for Tenosynovial Giant Cell Tumor(MOTION) | active not recruiting | Phase 3 | 123 | Deciphera Pharmaceuticals, LLCINDUSTRY | 13 | Mar 20, 2026 | clinicaltrials |
| NCT04192344 | A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-021 in Patients With Advanced Solid Tumor | recruiting | Phase 1 | 276 | Abbisko Therapeutics Co, LtdINDUSTRY | 2 | Mar 19, 2026 | clinicaltrials |
| NCT01207492 | Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor | completed | Phase 2 | 17 | Andrew J. Wagner, MD, PhDOTHER | 1 | Feb 20, 2026 | clinicaltrials |
| NCT07315841 | Accuracy of Indocyanine Green (ICG) Fluorescence Imaging in Tenosynovial Giant Cell Tumor Surgery(ICG-TGCT) | recruiting | Phase 4 | 40 | Shanghai Jiao Tong University Affiliated Sixth People's HospitalOTHER | 1 | Jan 5, 2026 | clinicaltrials |
| NCT04635111 | A Long-term Study Evaluating Hepatotoxicity Associated With TURALIO™ (Pexidartinib) Treatment | recruiting | — | 30 | Daiichi SankyoINDUSTRY | 1 | Oct 6, 2025 | clinicaltrials |
| NCT04526704 | Study to Evaluate Discontinuation and Re-Treatment in Participants With Tenosynovial Giant Cell Tumor (TGCT) Previously Treated With Pexidartinib(PLX3397) | completed | Phase 4 | 32 | Daiichi SankyoINDUSTRY | 7 | Dec 30, 2024 | clinicaltrials |
| NCT05349643 | A Study to Evaluate Safety and Efficacy of AMB-05X Injections in Subjects With TGCT | completed | Phase 2 | 20 | AmMax Bio, Inc.INDUSTRY | 3 | Jul 5, 2024 | clinicaltrials |
| NCT04731675 | An Open-Label Study of Intra-articular AMB-05X Injections in Subjects With Tenosynovial Giant Cell Tumor of the Knee | completed | Phase 2 | 11 | AmMax Bio, Inc.INDUSTRY | 4 | Jun 27, 2024 | clinicaltrials |
| NCT04938180 | A Phase 2 Study of Intravenous AMB-05X in Tenosynovial Giant Cell Tumor Patients | terminated | Phase 2 | 4 | AmMax Bio, Inc.INDUSTRY | 3 | May 24, 2024 | clinicaltrials |
| NCT04952896 | Clinical Study of Magnetic Resonance Imaging and Deep Learning of Joint Synovial Disease | completed | — | 350 | Peking University Third HospitalOTHER | 1 | Nov 2, 2022 | clinicaltrials |
| NCT02371369 | Phase 3 Study of Pexidartinib for Pigmented Villonodular Synovitis (PVNS) or Giant Cell Tumor of the Tendon Sheath (GCT-TS)(ENLIVEN) | completed | Phase 3 | 120 | Daiichi SankyoINDUSTRY | 12 | May 11, 2022 | clinicaltrials |
| NCT02471716 | Study of Cabiralizumab in Patients With Pigmented Villonodular Synovitis / Diffuse Type Tenosynovial Giant Cell Tumor(FPA008-002) | completed | Phase 1 / Phase 2 | 66 | Five Prime Therapeutics, Inc.INDUSTRY | 6 | Aug 31, 2021 | clinicaltrials |
| NCT04955535 | Screening of Specific Genes for Pigmented Villous Nodular Synovitis | completed | — | 60 | Peking University Third HospitalOTHER | 1 | Jul 8, 2021 | clinicaltrials |
| NCT01643850 | MCS110 in Patients With Pigmented Villonodular Synovitis (PVNS) | completed | Phase 2 | 36 | Novartis PharmaceuticalsINDUSTRY | 2 | Jan 5, 2021 | clinicaltrials |
| NCT01804530 | Phase 1 Study of PLX7486 as Single Agent in Patients With Advanced Solid Tumors | terminated | Phase 1 | 59 | PlexxikonINDUSTRY | 1 | Aug 2, 2018 | clinicaltrials |
| NCT02673736 | A Study of PLX73086 in Advanced Solid Tumors and Locally Advanced or Refractory Tenosynovial Giant Cell Tumor | terminated | Phase 1 | 11 | PlexxikonINDUSTRY | 1 | Aug 2, 2018 | clinicaltrials |
| NCT01261429 | Study of Nilotinib Efficacy in Pigmented Villo-Nodular Synovitis/ Tenosynovial Giant Cell Tumour (PVNS/TGCT) | completed | Phase 2 | 50 | Centre Leon BerardOTHER | 5 | Apr 16, 2013 | clinicaltrials |